Search results
Results from the WOW.Com Content Network
Research and analyze stocks to buy If you’re interested in buying individual stocks, you’ll need to research and figure out if the stock is a good buy or a “goodbye.” And that can take a ...
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Genentech (DNA) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy Genentech for $46.8 billion. Genentech's board approved and recommended the deal, which offers $95 per share ...
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals: Allergan, Inc: 49.4 64
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Berkshire Hathaway wasn’t one of them. The 10 stocks that made ...
Later, in September, Genentech announced it would acquire Arrayit Corporation. [ 38 ] On 7 April 2014, Roche announced its intention to acquire IQuum for up to $450 million, [ 39 ] as well as the rights to an experimental drug (ORY-1001) from Spanish company Oryzon Genomics for $21 million and up to $500 million in milestone payments. [ 40 ]
Once the stock is trading on the exchange, small-fry investors and big-time professionals have plenty of opportunities to buy shares. In fact, waiting for a stock’s actual debut can be a smaller ...